The efficacy and safety of sintilimab plus regorafenib in refractory metastatic colorectal cancer.

被引：0
|
作者：
Li, Rongrong
Liu, Zhenyang
Yin, Xianli
Zeng, Deyu
Jiang, Shaofeng
Liu, Wu
机构：
[1] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Hosp, Changsha, Peoples R China
[2] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Hosp,Dept Med Oncol, Changsha, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E15546 / E15546
页数：1
相关论文
共 50 条
  • [1] A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer
    Xue, Wu-Song
    Men, Si-Ye
    Liu, Wei
    Liu, Reng-Hai
    MEDICINE, 2018, 97 (40)
  • [2] A single-arm study on the efficacy and safety of regorafenib plus sintilimab as salvage-line treatments in non-MSI-H metastatic colorectal cancer.
    Liu, Rui
    Wang, Xia
    Ji, Zhi
    Deng, Ting
    Zhang, Le
    Yang, Yuchong
    Ning, Tao
    Bai, Ming
    Ge, Shaohua
    Li, Hongli
    Duan, Jingjing
    Ba, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Case report: Efficacy and safety of regorafenib plus fluorouracil combination therapy in the treatment of refractory metastatic colorectal cancer
    Haque, Emaan
    Muhsen, Ibrahim N.
    Esmail, Abdullah
    Umoru, Godsfavour
    Mylavarapu, Charisma
    Ajewole, Veronica B.
    Abdelrahim, Maen
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [4] Efficacy and safety of regorafenib compared to TAS-102 for refractory metastatic colorectal cancer
    Abrahao, Ana Beatriz Kinupe
    Ko, Yoo-Joung
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Efficacy and Safety of the Oral Multikinase Regorafenib in Metastatic Colorectal Cancer
    Cicero, Giuseppe
    De Luca, Rossella
    Dieli, Francesco
    ONCOLOGY, 2017, 93 (06) : 354 - 358
  • [6] A phase ib trial to evaluate the safety and efficacy of quinacrine plus capecitabine in patients with refractory metastatic colorectal cancer.
    Winer, Arthur
    Vijayvergia, Namrata
    Cohen, Steven J.
    Denlinger, Crystal S.
    Astsaturov, Igor A.
    Dotan, Efrat
    Gallant, Jean-Nicolas
    Wang, Edward W.
    Kunkel, Miriam
    Lim, Bora
    Harvey, Harold A.
    Sivik, Jeffrey Michael
    Zhou, Lanlan
    Korzekwa, Kenneth
    Ruth, Karen
    Ross, Eric A.
    El-Deiry, Wafik S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Safety and efficacy of ONO-4578 plus nivolumab in metastatic colorectal cancer.
    Kawazoe, Akihito
    Takashima, Atsuo
    Matsuoka, Hiroshi
    Hamamoto, Yasuo
    Okuno, Tatsuya
    Hamaguchi, Tetsuya
    Yamaguchi, Kensei
    Oki, Eiji
    Sugimoto, Naotoshi
    Tsuji, Yasushi
    Boku, Shogen
    Nishina, Tomohiro
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 93 - 93
  • [8] Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies
    Sueda, Toshinori
    Sakai, Daisuke
    Kudo, Toshihiro
    Sugiura, Takashi
    Takahashi, Hidekazu
    Haraguchi, Naotsugu
    Nishimura, Junichi
    Hata, Taishi
    Hayashi, Taro
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Masaki
    Satoh, Taroh
    ANTICANCER RESEARCH, 2016, 36 (08) : 4299 - 4306
  • [9] Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review
    Skarderud, Maria Roed
    Polk, Anne
    Vistisen, Kirsten Kjeldgaard
    Larsen, Finn Ole
    Nielsen, Dorte Lisbet
    CANCER TREATMENT REVIEWS, 2018, 62 : 61 - 73
  • [10] A retrospective comparison between regorafenib and TAS-102 for refractory metastatic colorectal cancer.
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Hamauchi, Satoshi
    Komori, Azusa
    Kito, Yosuke
    Mitani, Seiichiro
    Hasegawa, Hiroko
    Narita, Yukiya
    Kadowaki, Shigenori
    Ura, Takashi
    Ando, Masashi
    Mori, Keita
    Tajika, Masahiro
    Yasui, Hirofumi
    Muro, Kei
    Yamazaki, Kentaro
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345